Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Un estudio que evalúa las características de la enfermedad y los resultados en participantes con asma en la práctica clínica habitual (AIRITY)

4 de noviembre de 2026 actualizado por: Sanofi

Estudio transversal y prospectivo híbrido para evaluar las características de los pacientes, la carga de la enfermedad, el control de la enfermedad, los fenotipos, los endotipos y los resultados en un entorno real en pacientes con asma

The main aim of the study to describe the characteristics of participants with asthma across the spectrum of disease severity, including sociodemographic and clinical characteristics, treatment and disease burden, biomarkers, and both disease-specific and generic health-related quality of life.

The study consists of two parts: a cross-sectional study, and a prospective follow-up evaluate changes in disease trajectories in participants with asthma.

Descripción general del estudio

Tipo de estudio

De observación

Inscripción (Estimado)

2500

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Trial Transparency email recommended-Toll free for US & Canada
  • Número de teléfono: 6 800-633-1610
  • Correo electrónico: Contact-US@sanofi.com

Ubicaciones de estudio

    • Bayern (Bavaria)
      • München, Bayern (Bavaria), Alemania, 85039
        • Reclutamiento
        • Investigational Site Number: 276503
    • North Rhine-Westphalia
      • Bonn, North Rhine-Westphalia, Alemania, 53119
        • Reclutamiento
        • Investigational Site Number: 276505
    • Saxony
      • Hohenstein-Ernstthal, Saxony, Alemania, 09337
        • Reclutamiento
        • Investigational Site Number: 276501
    • Schleswig-Holstein
      • Schleswig, Schleswig-Holstein, Alemania, 24837
        • Reclutamiento
        • Investigational Site Number: 276502
    • Alberta
      • Calgary, Alberta, Canadá, T3R 1W7
        • Reclutamiento
        • Investigational Site Number: 124203
    • Ontario
      • Windsor, Ontario, Canadá, N8X 2G1
        • Reclutamiento
        • Investigational Site Number: 124201
    • Quebec
      • Trois-Rivières, Quebec, Canadá, G8T7A1
        • Reclutamiento
        • Investigational Site Number: 124204
      • Madrid, España, 28034
        • Reclutamiento
        • Investigational Site Number: 724408
    • Alabama
      • Bessemer, Alabama, Estados Unidos, 35022
        • Reclutamiento
        • Trinity Clinical Research, LLC - Bessemer - Site Number: 840150
    • Arizona
      • Chandler, Arizona, Estados Unidos, 85224
        • Retirado
        • Chandler Clinical Trials - Site Number: 840106
      • Mesa, Arizona, Estados Unidos, 85206
        • Activo, no reclutando
        • Del Sol Research Management, LLC - Mesa - Site Number: 840123
      • Scottsdale, Arizona, Estados Unidos, 85254
        • Reclutamiento
        • Orso Health - Scottsdale - Site Number: 840133
      • Sun City, Arizona, Estados Unidos, 85351
        • Activo, no reclutando
        • Sun City Clinical Trials - Elite - Site Number: 840120
    • California
      • California City, California, Estados Unidos, 91107
        • Activo, no reclutando
        • FOMAT - Huntington Asthma & Allergy Center - Site Number: 840158
      • La Palma, California, Estados Unidos, 90623
        • Activo, no reclutando
        • Imax Clinical Trials - Site Number: 840109
      • Los Angeles, California, Estados Unidos, 90017
        • Activo, no reclutando
        • Downtown LA Research - Site Number: 840161
      • Newport Beach, California, Estados Unidos, 92663
        • Activo, no reclutando
        • Newport Native MD, Inc. - Site Number: 840101
      • Pasadena, California, Estados Unidos, 91101
        • Activo, no reclutando
        • Pasadena Clinical Trials - Site Number: 840116
      • Tarzana, California, Estados Unidos, 91356
        • Retirado
        • Valiance Clinical Research (JPJ Research) - Site Number: 840135
      • Walnut Creek, California, Estados Unidos, 94598
        • Activo, no reclutando
        • Clinical Research of California - Site Number: 840145
    • Florida
      • Altamonte Springs, Florida, Estados Unidos, 32701
        • Activo, no reclutando
        • Cornerstone Research Institute, LLC - Site Number: 840152
      • Boca Raton, Florida, Estados Unidos, 33431
        • Activo, no reclutando
        • 3SYNC Research - Boca Raton - Site Number: 840148
      • Brandon, Florida, Estados Unidos, 33511
        • Activo, no reclutando
        • Meris Clinical Research - Site Number: 840167
      • Greenacres City, Florida, Estados Unidos, 33467
        • Activo, no reclutando
        • Finlay Medical Research - Site Number: 840107
      • Miami, Florida, Estados Unidos, 33126
        • Activo, no reclutando
        • EMDA Clinical Research - Site Number: 840113
      • Miami, Florida, Estados Unidos, 33126
        • Activo, no reclutando
        • Finlay Medical Research - Miami - Site Number: 840110
      • Miami, Florida, Estados Unidos, 33130
        • Activo, no reclutando
        • Care Research Inc. - Site Number: 840103
      • Miami, Florida, Estados Unidos, 33142
        • Activo, no reclutando
        • L&A Morales Healthcare, Inc - Site Number: 840102
      • Miami, Florida, Estados Unidos, 33145
        • Activo, no reclutando
        • MedOne Clinical Research - Site Number: 840122
      • Miami, Florida, Estados Unidos, 33155
        • Activo, no reclutando
        • D&H National Research Centers INC - Site Number: 840128
      • Miami, Florida, Estados Unidos, 33173
        • Activo, no reclutando
        • Research Institute Of South Florida - Site Number: 840149
      • Miami, Florida, Estados Unidos, 33174
        • Activo, no reclutando
        • Valencia Medical & Research Center, Corp - Site Number: 840153
      • Miami, Florida, Estados Unidos, 33186
        • Activo, no reclutando
        • Correa Research Center, Inc. - Site Number: 840141
      • Miami Gardens, Florida, Estados Unidos, 33014
        • Activo, no reclutando
        • Pro Care Research Center - Site Number: 840143
      • Miami Lakes, Florida, Estados Unidos, 33014
        • Activo, no reclutando
        • 3SYNC Research - Miami Lakes - Site Number: 840146
      • Miami Lakes, Florida, Estados Unidos, 33014
        • Activo, no reclutando
        • Deluxe Health Center - Site Number: 840117
      • Miami Lakes, Florida, Estados Unidos, 33016
        • Activo, no reclutando
        • MedQuest Translation Sciences, LLC - Site Number: 840162
      • North Miami Beach, Florida, Estados Unidos, 33169
        • Activo, no reclutando
        • Biscayne Clinical Research - Site Number: 840157
      • Palm Springs, Florida, Estados Unidos, 33406
        • Activo, no reclutando
        • CTMD Research, Inc - Site Number: 840147
      • Plantation, Florida, Estados Unidos, 33317
        • Activo, no reclutando
        • Edward Jenner Research Group, LLC - Site Number: 840169
      • Port Saint Lucie, Florida, Estados Unidos, 34986
        • Activo, no reclutando
        • Mark J. Pamer D.O., LLC - Site Number: 840121
      • Tamarac, Florida, Estados Unidos, 33321
        • Activo, no reclutando
        • TBC Research Corp - Site Number: 840132
      • Tampa, Florida, Estados Unidos, 33613
        • Activo, no reclutando
        • Avita Clinical Research - Tampa - Site Number: 840125
      • West Palm Beach, Florida, Estados Unidos, 33409
        • Activo, no reclutando
        • Palm Beach Medical & Research Center, Inc. - Site Number: 840165
    • Georgia
      • Columbus, Georgia, Estados Unidos, 31904
        • Activo, no reclutando
        • The Allergy Center at Brookstone - Site Number: 840114
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60616
        • Activo, no reclutando
        • Next Innovation Clinical Research - Chicago - Site Number: 840159
    • Kentucky
      • Lexington, Kentucky, Estados Unidos, 40509
        • Activo, no reclutando
        • Bluegrass Allergy Care - Lexington - Site Number:840112
    • Maryland
      • Columbia, Maryland, Estados Unidos, 21045
        • Reclutamiento
        • Columbia Medical Practice - Site Number: 840172
      • Rockville, Maryland, Estados Unidos, 20854
        • Activo, no reclutando
        • Velocity Clinical Research - Rockville - Site Number: 840163
    • Michigan
      • Ann Arbor, Michigan, Estados Unidos, 48109
        • Reclutamiento
        • University of Michigan - Ann Arbor - Site Number: 840140
    • Montana
      • Missoula, Montana, Estados Unidos, 59808
        • Activo, no reclutando
        • Montana Medical Research - Site Number: 840137
    • Nebraska
      • Papillion, Nebraska, Estados Unidos, 68046
        • Activo, no reclutando
        • Primary Clinical Research, LLC - Papillion - Site Number: 840168
    • New Jersey
      • Sewell, New Jersey, Estados Unidos, 08080
        • Activo, no reclutando
        • MedCorps Asthma and Pulmonary Specialists LLC - Sewell - Site Number: 840136
    • New York
      • Cortland, New York, Estados Unidos, 13045
        • Activo, no reclutando
        • Finger Lakes Medical Research, PLLC - Site Number: 840155
      • New Windsor, New York, Estados Unidos, 12553
        • Activo, no reclutando
        • Mid Hudson Medical Research, PLLC - Site Number: 840139
      • New York, New York, Estados Unidos, 10029
        • Activo, no reclutando
        • Icahn School of Medicine at Mount Sinai - Center for Advanced Medicine - Site Number: 840119
    • North Carolina
      • Asheville, North Carolina, Estados Unidos, 28801
        • Activo, no reclutando
        • Allergy Partners of Western North Carolina - Site Number: 840131
      • Gastonia, North Carolina, Estados Unidos, 28054-7489
        • Activo, no reclutando
        • Clinical Research of Gastonia (CRG) - Site Number: 840160
      • Greenville, North Carolina, Estados Unidos, 27834-2849
        • Reclutamiento
        • East Carolina University Physicians - Pulmonary and Critical Care Medicine - Site Number: 840142
    • Ohio
      • Lima, Ohio, Estados Unidos, 45801
        • Activo, no reclutando
        • NexGen Research - Site Number: 840154
      • Toledo, Ohio, Estados Unidos, 43617
        • Activo, no reclutando
        • Toledo Institute of Clinical Research Inc - Site Number: 840105
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Estados Unidos, 15241
        • Activo, no reclutando
        • Allergy and Clinical Immunology Associates - Site Number: 840127
    • South Carolina
      • Rock Hill, South Carolina, Estados Unidos, 29732
        • Activo, no reclutando
        • Clinical Research of Rock Hill - Site Number: 840115
    • Tennessee
      • Tennessee City, Tennessee, Estados Unidos, 30909
        • Activo, no reclutando
        • Allergy Associates, PA dba Allergy, Asthma and Sinus Center - Site Number: 840144
    • Texas
      • Dallas, Texas, Estados Unidos, 75235
        • Activo, no reclutando
        • Southwest Family Medicine Associates - Site Number: 840126
      • El Paso, Texas, Estados Unidos, 79902
        • Activo, no reclutando
        • El Paso Pulmonary Association (EPPA) - West El Paso - Site Number: 840108
      • Houston, Texas, Estados Unidos, 77090
        • Activo, no reclutando
        • Lumi Research - Site Number: 840156
      • Houston, Texas, Estados Unidos, 77099
        • Activo, no reclutando
        • Pioneer Research Solutions - Site Number: 840104
      • Hurst, Texas, Estados Unidos, 76054
        • Activo, no reclutando
        • Lumi Research - Hurst - Site Number: 840164
      • Tomball, Texas, Estados Unidos, 77081
        • Activo, no reclutando
        • DM Clinical - Tomball - Site Number: 840130
    • Washington
      • Bellingham, Washington, Estados Unidos, 98225
        • Activo, no reclutando
        • Bellingham Asthma, Allergy & Immunology Clinic - Site Number: 840138
    • Brittany Region
      • Brest, Brittany Region, Francia, 29200
        • Reclutamiento
        • Investigational Site Number: 250603
    • Occitanie
      • Lunel, Occitanie, Francia, 34400
        • Reclutamiento
        • Investigational Site Number: 250612
      • Toulouse, Occitanie, Francia, 31059
        • Reclutamiento
        • Investigational Site Number: 250607
    • Pays de la Loire Region
      • La Roche-sur-Yon, Pays de la Loire Region, Francia, 85000
        • Reclutamiento
        • Investigational Site Number: 250613
    • Île-de-France Region
      • Argenteuil, Île-de-France Region, Francia, 95100
        • Reclutamiento
        • Investigational Site Number: 250616
      • Créteil, Île-de-France Region, Francia, 94010
        • Reclutamiento
        • Investigational Site Number: 250609
      • Niigata, Japón
        • Reclutamiento
        • Investigational Site Number: 392707
    • Fukuoka
      • Kitakyushu-Shi, Fukuoka, Japón, 802-0083
        • Reclutamiento
        • Investigational Site Number: 392705
    • Kagawa-ken
      • Takamatsu, Kagawa-ken, Japón, 761-8073
        • Reclutamiento
        • Investigational Site Number: 392702
    • Saga-ken
      • Saga, Saga-ken, Japón, 849-8501
        • Reclutamiento
        • Investigational Site Number: 392711
    • Tokyo
      • Bunkyo-ku, Tokyo, Japón, 113-8431
        • Reclutamiento
        • Investigational Site Number: 392710
      • tabashi City, Tokyo, Japón, 173-8610
        • Reclutamiento
        • Investigational Site Number: 392709

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

6 años y mayores (Niño, Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

Enrollment into Part 1 is planned to achieve a balanced distribution of participants across participating regions, to the extent feasible. In addition, enrollment is intended to include pediatric participants, adolescents, and adults. Enrollment into Part 2 is planned to achieve a balanced distribution of participants across participating regions, to the extent feasible.

Descripción

Inclusion Criteria:

Applicable for Part 1 participants:

  • Age 6 years and older, at the time of signing the informed consent
  • Physician diagnosis of asthma for at least 12 months
  • Existing treatment with low, medium, or high dose ICS and other asthma therapies as reflected in GINA 2-5 steps
  • Participant or legally authorized representative (where applicable) has consented to participate

Applicable for Part 2 participants:

  • Age 18 years and older, at the time of signing the informed consent.
  • Physician diagnosis of asthma for at least 12 months
  • Existing treatment with low or medium ICS and other asthma therapies as reflected in GINA 2-4 steps
  • Participant or legally authorized representative (where applicable) has consented to participate
  • Participants must meet the criteria for at least one of the cohorts below:

A) Asthma control cohorts

  1. ACQ-5 >= 1.5
  2. ACQ-5 < 1.5 (B) Type-2 biomarker cohorts
  3. Elevated T2 biomarkers (B1: Type-2-high cohort)
  4. Low T2 biomarkers (B2: Type-2-low cohort)

Participants are excluded from the study if any of the following criteria apply (applicable for both Part 1 and Part 2 participants):

  • Current diagnosis of chronic obstructive pulmonary disease (COPD) or congestive heart failure
  • Participants with moderate/severe cognitive impairment.
  • Participants with moderate/severe cardiac disease.
  • Participants on immunosuppressive medication for a chronic condition.
  • Participation in other interventional and noninterventional clinical study (currently or in the past 3 months)

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: COHORT
  • Perspectivas temporales: PROSPECTIVE

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
Part-1: Participants With Asthma

Participants receiving treatment with low-, medium-, or high-dose inhaled corticosteroids (ICS) and/or biologic therapies as part of standard of care (SoC) for the management of asthma in routine clinical practice.

Participant- and physician-reported outcomes will be collected per protocol. No Investigational Medicinal Product (IMP) administration.

Participant- and physician-reported outcomes, blood samples/lung tests and other optional assessments will be collected per protocol. No IMP administration.

Part-2: A1- Uncontrolled Asthma Cohort

Participants receiving SoC with Asthma Control Questionnaire-5 (ACQ-5) threshold of greater than or equal to (>=)1.5

Participant- and physician-reported outcomes will be collected per protocol. No Investigational Medicinal Product (IMP) administration.

Participant- and physician-reported outcomes, blood samples/lung tests and other optional assessments will be collected per protocol. No IMP administration.

Part-2: A2- Controlled Asthma Cohort

Participants receiving SoC with Asthma Control Questionnaire-5 (ACQ-5) threshold of less than (<)1.5

Participant- and physician-reported outcomes will be collected per protocol. No Investigational Medicinal Product (IMP) administration.

Participant- and physician-reported outcomes, blood samples/lung tests and other optional assessments will be collected per protocol. No IMP administration.

Part-2: B1- Type-2 (T2) High Asthma Cohort

Participants receiving SoC with elevated T2 biomarkers

Participant- and physician-reported outcomes will be collected per protocol. No Investigational Medicinal Product (IMP) administration.

Participant- and physician-reported outcomes, blood samples/lung tests and other optional assessments will be collected per protocol. No IMP administration.

Part-2: B2- Type-2 Low Asthma Cohort

Participants receiving SoC with low T2 biomarkers

Participant- and physician-reported outcomes will be collected per protocol. No Investigational Medicinal Product (IMP) administration.

Participant- and physician-reported outcomes, blood samples/lung tests and other optional assessments will be collected per protocol. No IMP administration.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Part 1: Descriptive Characterization of Participants With Asthma Across the Spectrum of Severities
Periodo de tiempo: Part 1: At baseline

Descriptive Statistical Analyses may include sociodemographic and clinical characteristics, comorbidities, exacerbation history, medication burden, biomarkers and lung function.

Part 1: At baseline
Part 1: ACQ-5 Scores to Evaluate Characteristics of Participants With Asthma
Periodo de tiempo: Part 1: At baseline

ACQ-5 is a 5-question survey. The five ACQ-5 questions are scored on a 6-point scale (0 = good control, 6 = poor control), and the overall score is the mean of the five responses. Participant's scores are then classified into three prescribed groups as having well-controlled asthma (score ≤ 0.75); partially controlled asthma (score 0.75-1.5), or not well controlled asthma (score >1.5). A change in ACQ-5 score of 0.5 is considered the minimal clinically important difference (MCID)

Part 1: At baseline
Part 1: Mini-Asthma Quality of Life Questionnaire (Mini-AQLQ) Scores to Evaluate Characteristics of Participants With Asthma
Periodo de tiempo: Part 1: At baseline

The Asthma Quality of Life Questionnaire (AQLQ) includes 32 items, The mini-AQLQ is a reduced version of the AQLQ which includes 15 items. The questions correspond to 4 dimensions of health: symptoms (5 items), limitation of usual activities (4 items), emotional function (3 items) and environmental stimuli (3 items). The response options for each item are on an equidistant scale of 7 points, where 1 corresponds to the maximum disability and 7 to the absence of disability. Higher scores indicating better quality of life (less impairment) and lower scores indicating worse quality of life (greater impairment).

Part 1: At baseline
Part 1: Physician Global Assessment of Asthma Severity and Symptom Control
Periodo de tiempo: Part 1: At baseline

Asthma severity, asthma control, and comorbidity will be assessed using three global impression of severity items: Physician Global Impression of Severity (PhGIS) - asthma severity. PhGIS - asthma control, and PhGIS - comorbidity.

Part 1: At baseline
Part 2: Descriptive Statistical Analysis of Difference in Asthma Symptom Control (ACQ-5) Between Part 2 Cohorts A1 and A2
Periodo de tiempo: Part 2: At Weeks 52 and 104

Data on participant's asthma symptoms and control will be collected via the ACQ-5, 5-question survey. The five ACQ-5 questions are scored on a 6-point scale (0 = good control, 6 = poor control), and the overall score is the mean of the five responses. Participant's scores are then classified into three prescribed groups as having well-controlled asthma (score <=0.75); partially controlled asthma (score 0.75-1.5), or not well controlled asthma (score >1.5). A change in ACQ-5 score of 0.5 is considered the MCID.

Part 2: At Weeks 52 and 104
Part 2: Number of Participants Analyzed with Treatment Utilization Pattern between Part 2 Cohorts A1 and A2
Periodo de tiempo: Part 2: At Weeks 52 and 104

Treatment utilization will include systemic corticosteroids (SCS), ICS, and short-acting beta agonists (SABA). Number of participants with various treatment utilization pattern will be assessed and reported.

Part 2: At Weeks 52 and 104
Part 2: Descriptive Statistical Analysis of Difference in Change in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (Pre-BD FEV₁) between Part 2 Cohorts B1 and Cohort B2
Periodo de tiempo: Part-2: At Weeks 52 and 104

Pre-BD FEV₁ is the forced expiratory volume in 1 second measured by spirometry prior to bronchodilator administration.

Part-2: At Weeks 52 and 104

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Parte 1: Número de participantes caracterizados por sus datos demográficos y características clínicas
Periodo de tiempo: Parte 1: Desde 12 meses antes de la inscripción en el estudio
Parte 1: Desde 12 meses antes de la inscripción en el estudio
Parte 1: Número de participantes caracterizados por su carga de enfermedad, estado de salud, experiencias de tratamiento
Periodo de tiempo: Parte 1: Desde 12 meses antes de la inscripción en el estudio
Parte 1: Desde 12 meses antes de la inscripción en el estudio
Parte 1: Número de Participantes Caracterizados por el Uso de Medicación
Periodo de tiempo: Parte 1: Desde 12 meses antes de la inscripción al estudio
Parte 1: Desde 12 meses antes de la inscripción al estudio
Parte 1: Número de participantes caracterizados por su estilo de vida e influencias ambientales
Periodo de tiempo: Parte 1: Desde 12 meses antes de la inscripción al estudio
Parte 1: Desde 12 meses antes de la inscripción al estudio
Parte 1: Número de participantes caracterizados por el uso de corticosteroides inhalados y sistémicos
Periodo de tiempo: Parte 1: Desde 12 meses antes de la inscripción al estudio
Parte 1: Desde 12 meses antes de la inscripción al estudio
Parte 1: Número de participantes caracterizados por Utilización de Recursos Sanitarios (URS)
Periodo de tiempo: Parte 1: Desde 12 meses antes de la inscripción al estudio
Parte 1: Desde 12 meses antes de la inscripción al estudio
Parte 2: Caracterización descriptiva que incluye datos sociodemográficos, características de la enfermedad e historial de tratamiento.
Periodo de tiempo: Parte 2: Al inicio del estudio
Parte 2: Al inicio del estudio
Parte 2: Tasas de Exacerbación Anualizadas en las Semanas 52 y 104
Periodo de tiempo: Parte 2: En las semanas 52 y 104
Parte 2: En las semanas 52 y 104
Parte 2: Número de participantes analizados para cambios en la carga de corticosteroides inhalados y sistémicos
Periodo de tiempo: Parte 2: Desde el inicio hasta la semana 104
Parte 2: Desde el inicio hasta la semana 104
Parte 2: Cambios en el nivel del biomarcador
Periodo de tiempo: Parte 2: En las semanas 52 y 104
Parte 2: En las semanas 52 y 104
Part 1: Physician-Reported Outcomes to Characterize Physician Perspectives
Periodo de tiempo: Part 1: From 12 months prior to study enrollment

The treatment preferences for participant profiles, an assessment of perceived disease burden on participants, an evaluation of barriers to optimal treatment, and treatment adherence and persistence will be collected from the main treating physician.

Part 1: From 12 months prior to study enrollment
Part 1: Change From Baseline in Patient Global Impression of Severity (PGIS) Score
Periodo de tiempo: Part 1: From 12 months prior to study enrollment

The PGIS is a single question asking the participant to rate their severity and symptom control. The PGIS is a 5-point ordinal scale ranging from 1 (No symptoms) to 5 (Very severe symptoms). Higher scores indicate greater symptom severity.

Part 1: From 12 months prior to study enrollment
Part 1: Change From Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) Score
Periodo de tiempo: Part 1: From 12 months prior to study enrollment

The WPAI-Asthma is an Asthma-specific, patient-reported measure of work absenteeism, work presenteeism (reduced productivity while working due to illness), total work productivity loss (absenteeism plus presenteeism), and overall activity impairment over the prior 7 days. The WPAI-Asthma questionnaire score represents the percentage of impairment, from 0 to 100%. Higher scores represent greater impairment and less productivity.

Part 1: From 12 months prior to study enrollment
Part 2: Changes From Baseline to Week 104 in Pre and Post Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)
Periodo de tiempo: Part 2: From baseline to week 52 and week 104

FEV1 will be measured in Liters. Change from baseline: mean of (value of observed FEV1 at treatment duration minus baseline value).

Part 2: From baseline to week 52 and week 104
Part 2: Number of Participants With Significant Changes in Asthma Treatment Patterns at Week 52 and Week 104
Periodo de tiempo: Part 2: From baseline to week 52 and week 104

Changes in treatment patterns including use of SCS, ICS, other asthma therapies, and rescue medication. Treatment escalation (for example [e.g.], ICS dose changes, addition of asthma therapies, or biologic prescription), treatment adherence, and treatment persistence will be assessed from baseline to Week 52 and Week 104 in participants with Asthma.

Part 2: From baseline to week 52 and week 104
Part 2: Changes in Physician Global Assessment of Asthma Severity, Symptom Control and Comorbidities (PhGIS)
Periodo de tiempo: Part 2: From baseline to week 52 and week 104

Asthma severity, asthma control, and comorbidity will be assessed using three global impression of severity items: PhGIS - asthma severity. PhGIS - asthma control, and PhGIS - comorbidity.

Part 2: From baseline to week 52 and week 104
Part 2: Number of Participants With Comorbidities and Burden of Comorbidities Based on the Participant Survey Using the PGIS scale
Periodo de tiempo: Part 2: At Weeks 52 and 104

The PGIS is a single question asking the participant to rate their severity and symptom control. The PGIS is a 5-point ordinal scale ranging from 1 (No symptoms) to 5 (Very severe symptoms). Higher scores indicate greater symptom severity.

Part 2: At Weeks 52 and 104
Part 2: Number of Participants With Comorbidities and Burden of Comorbidities Based on the Physician Survey Using the PhGIS Scale
Periodo de tiempo: Part 2: At Weeks 52 and 104

Asthma severity, asthma control, and comorbidity will be assessed using three global impression of severity items: PhGIS - asthma severity. PhGIS - asthma control, and PhGIS - comorbidity.

Part 2: At Weeks 52 and 104
Part 2: Changes in Physician-reported HCRU (Hospitalizations, Outpatient and Emergency Visits)
Periodo de tiempo: Part 2: From baseline to week 52 and week 104

Data about HCRU associated with medical encounters will be collected by physicians from medical records. The data collected will include setting, department, type of specialist, the reasons and duration of hospitalizations, outpatient and emergency room (ER) visits.

Part 2: From baseline to week 52 and week 104
Part 2: Changes in Patient-Reported Outcomes to Characterize Disease Evolution
Periodo de tiempo: Part 2: At Weeks 52 and 104

PROs used will include but not limited to ACQ-5, mini-AQLQ. ACQ-5 questions are scored on a 6-point scale (0 = good control, 6 = poor control), Mean of the five responses is the overall score. Scores are then classified into three groups as having well-controlled asthma (score <= 0.75); partially controlled asthma (score 0.75-1.5), or not well controlled asthma (score >1.5). AQLQ includes 32 items, The mini-AQLQ is a reduced version of the AQLQ which includes 15 items. The questions correspond to 4 dimensions of health: symptoms (5 items), limitation of usual activities (4 items), emotional function (3 items) and environmental stimuli (3 items). The response options for each item are on an equidistant scale of 7 points, where 1 corresponds to the maximum disability and 7 to the absence of disability.

Part 2: At Weeks 52 and 104
Part 2: Changes in Participant Survey Response
Periodo de tiempo: Part 2: From baseline to week 52 and week 104

Participant survey collecting demographics, clinical characteristics, disease burden, health status, treatment experiences, medication use and burden, work and school impacts, lifestyle and environmental influences, impacts on daily life, PGIS for each comorbidity and burden of comorbidities, inhaled and systemic corticosteroid burden (frequency of use, routes of administration, treatment satisfaction), and HCRU office visits, hospitalizations, outpatient and emergency visits will be collected from medical records.

Part 2: From baseline to week 52 and week 104

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Colaboradores

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

1 de abril de 2026

Finalización primaria (Estimado)

4 de abril de 2029

Finalización del estudio (Estimado)

4 de abril de 2029

Fechas de registro del estudio

Enviado por primera vez

31 de marzo de 2026

Primero enviado que cumplió con los criterios de control de calidad

21 de abril de 2026

Publicado por primera vez (Actual)

29 de abril de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

5 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

4 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • PIR21191
  • 2025-524916-13-00 (Ctis)
  • U1111-1336-5183 (Identificador de registro: ICTRP)
  • 2025 (Subvención/contrato del NIH de EE. UU.)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir